Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044837 · ClinicalTrials.gov registry record · Phase 1
Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women
A Phase 1 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Terminated
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
NCT00044837 is a Phase 1 study that was terminated before completion, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 120 participants.
The verdict
NCT00044837, a Phase 1 study, was terminated before completion, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if the anti-HIV drugs nelfinavir (NFV), lopinavir/ritonavir (LPV/r), and efavirenz (EFV) change the amount of estrogen in the blood when taken along with hormone replacement therapy (HRT) for menopause. HRT can be helpful for treating bothersome symptoms of menopause. However, it is not routinely used in HIV-infected postmenopausal women because it is not known how HRT interacts with anti-HIV drugs. The information obtained from this study will help doctors make recommendations for HRT in postmenopausal HIV-infected women.
Interventions
- DRUG Estradiol
- DRUG Medroxyprogesterone acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044837
The ClinicalTrials.gov registry entry for NCT00044837 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Estradiol is the first listed.
NCT00044837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00044837 about?
NCT00044837 is a clinical study titled "Hormone Replacement Therapy and Anti-HIV Drugs in HIV-Infected, Postmenopausal Women". The purpose of this study is to find out if the anti-HIV drugs nelfinavir (NFV), lopinavir/ritonavir (LPV/r), and efavirenz (EFV) change the amount of estrogen in the blood when taken along with hormone replacement therapy (HRT) for menopause. HRT can be helpful for treating bothersome symptoms of ...
What is the current status of trial NCT00044837?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 120 participants.
What interventions are being tested in trial NCT00044837?
The interventions under investigation include: Estradiol (DRUG), Medroxyprogesterone acetate (DRUG).
Who is sponsoring clinical trial NCT00044837?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.